Company Overview
XWELL, Inc. operates within the healthcare sector, specifically targeting the diagnostics and research industry by delivering health and wellness services to travelers across the United States and internationally. The company executes its business model through four distinct operational segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment is dedicated to providing comprehensive traveler's spa services, which include massage therapy, as well as nail and skin care services. As of the latest reporting period, the company maintains a market capitalization of $6.92M and employs a workforce of 246 individuals to support its operations. The combination of a $6.92M market cap and annual revenue of $29.52M indicates that XWELL, Inc. functions as a micro-cap entity with a relatively small market footprint. This valuation scale suggests the company is in an early-stage or niche position within the broader healthcare services landscape, where capital efficiency and operational focus are critical for survival and expansion.
Financial Health
XWELL, Inc. reported total revenue of $29.52M over the trailing twelve months, yet this generated a net income of $-17,395,000 and an EBITDA of $-9,209,000. The substantial negative gap between the positive revenue figure of $29.52M and the significant net loss reveals a highly leveraged cost structure where operating expenses and taxes far exceed gross profitability. The company generated free cash flow of $-8,783,000, which indicates a lack of financial flexibility and a reliance on external capital sources to fund day-to-day operations and capital expenditures. Profitability metrics further illustrate these challenges, with a gross margin of 19.3%, an operating margin of -3.8%, and a profit margin of -51.8%. The disparity between the 19.3% gross margin and the -51.8% profit margin highlights severe operational inefficiencies or high overhead costs that erode bottom-line earnings before interest and taxes. On the balance sheet, the company holds $4.22M in cash against $9.56M in total debt, resulting in a debt-to-equity ratio of 281.39. This leverage profile classifies the balance sheet as highly leveraged rather than conservative, exposing the firm to significant interest rate and refinancing risks. Liquidity is constrained, evidenced by a current ratio of 1.07, which suggests the company possesses only a slight buffer above current liabilities to meet short-term obligations. Return on Equity stands at -159.0% and return on assets is -22.5%, metrics that reveal management has not yet achieved positive capital allocation effectiveness due to persistent losses.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings and a forward P/E of -0.46. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in continued earnings deterioration or a complete restructuring of the earnings trajectory rather than standard growth expectations. The price-to-book ratio is recorded at -1.09, which indicates that the market values the company at a negative premium relative to its book value, a situation typically associated with distressed assets or companies with significant intangible liabilities. Alternative valuation multiples provide further insight, showing a price-to-sales ratio of 0.23 and an EV/EBITDA of -2.39, suggesting that the market is valuing the firm primarily on its revenue generation potential while discounting its earnings power heavily due to losses. The stock's trading range is defined by a 52-week high of $2.20 and a 52-week low of $0.26. Given the current price dynamics implied by the negative forward P/E and low price-to-sales ratio, the stock is currently trading significantly below the 52-week high of $2.20, reflecting a severe discount from its recent peak performance. The beta value of 0.86 indicates that the stock exhibits slightly lower volatility than the broader market, suggesting it is somewhat less sensitive to general market fluctuations despite its financial distress.
Growth & Income
The company experienced a revenue growth rate of -12.8% year-over-year, while earnings growth is listed as N/A due to the absence of positive earnings in the prior period. Since earnings are negative, there is no growth trajectory to compare against revenue, implying that the decline in revenue has directly contributed to the deepening of losses rather than being offset by margin expansion. As a non-dividend payer, the company does not distribute a dividend yield, which is listed as N/A, nor does it maintain a payout ratio of 0.0%. This lack of dividend distribution means the company is not returning cash to shareholders but is instead retaining any available cash flow, albeit limited, to attempt to fund operations and potentially restructure its balance sheet. The overall growth and income profile for XWELL, Inc. is characterized by negative revenue momentum, a complete absence of profit distribution, and significant capital consumption rather than capital return.